| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10014315 | HBV | ENSG00000081248.13 | protein_coding | CACNA1S | No | No | 779 | B1ALM3 Q13698 |
| TVIS10014316 | HBV | ENSG00000081248.13 | protein_coding | CACNA1S | No | No | 779 | B1ALM3 Q13698 |
| TVIS30087325 | HIV | ENSG00000081248.13 | protein_coding | CACNA1S | No | No | 779 | B1ALM3 Q13698 |
| TVIS30026316 | HIV | ENSG00000081248.13 | protein_coding | CACNA1S | No | No | 779 | B1ALM3 Q13698 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CACNA1S |
|---|---|
| DrugBank ID | DB01023 |
| Drug Name | Felodipine |
| Target ID | BE0002355 |
| UniProt ID | Q13698 |
| Regulation Type | inhibitor |
| PubMed IDs | 16675661 |
| Citations | Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. |
| Groups | Approved; Investigational |
| Direct Classification | Dihydropyridinecarboxylic acids and derivatives |
| SMILES | CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC |
| Pathways | Felodipine Metabolism Pathway; Felodipine Action Pathway |
| PharmGKB | PA449591 |
| ChEMBL | CHEMBL1480 |
